HIF-1α inhibition sensitizes pituitary adenoma cells to temozolomide by regulating MGMT expression

Oncology Reports

Volumn 30, Issue 5, 2013, Pages 2495-2501

  Chen, Wenna ^a   Xiao, Zheng ^a   Zhao, Yachao ^a   Huang, Lina ^a   Du, Ganqin ^a  

^a HENAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

HIF 1 ; MGMT; Pituitary adenoma; Temozolomide

Indexed keywords

2 METHOXYESTRADIOL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; RAD51 PROTEIN; TEMOZOLOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CASE REPORT; CELL VIABILITY; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DRUG EFFICACY; DRUG SENSITIZATION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; TRANSSPHENOIDAL SURGERY; TUMOR CELL; TUMOR XENOGRAFT; WESTERN BLOTTING;

ADULT; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL SURVIVAL; DACARBAZINE; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MICE; PITUITARY NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 84885028406     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2689     Document Type: Article

References (30)

1. Selman WR, Laws ER Jr, Scheithauer BW and Carpenter SM: The occurrence of dural invasion in pituitary adenomas. J Neurosurg 64: 402-407, 1986.
2. Scheithauer BW, Kovacs KT, Laws ER Jr and Randall RV: Pathology of invasive pituitary tumors with special reference to functional classification. J Neurosurg 65: 733-744, 1986.
3. Kreutzer J and Fahlbusch R: Diagnosis and treatment of pituitary tumors. Curr Opin Neurol 17: 693-703, 2004.
4. Ekeblad S, Sundin A, Janson ET, Welin S, Granberg D, Kindmark H, Dunder K, Kozlovacki G, Orlefors H, Sigurd M, Oberg K, Eriksson B and Skogseid B: Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 13: 2986-2991, 2007.
5. McCormack AI, McDonald KL, Gill AJ, Clark SJ, Burt MG, Campbell KA, Braund WJ, Little NS, Cook RJ, Grossman AB, Robinson BG and Clifton-Bligh RJ: Low O6-methylguanine- DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin Endocrinol 71: 226-233, 2009.
6. Syro LV, Uribe H, Penagos LC, Ortiz LD, Fadul CE, Horvath E and Kovacs K: Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm. Clin Endocrinol 65: 552-553, 2006.
7. Everhard S, Kaloshi G, Criniere E, Benouaich-Amiel A, Lejeune J, Marie Y, Sanson M, Kujas M, Mokhtari K, Hoang-Xuan K, Delattre JY and Thillet J: MGMT methylation: a marker of response to temozolomide in low-grade gliomas. Ann Neurol 60: 740-743, 2006.
8. Stupp R, Hegi ME, Gilbert MR and Chakravarti A: Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol 25: 4127-4136, 2007.
9. van Nifterik KA, van den Berg J, van der Meide WF, Ameziane N, Wedekind LE, Steenbergen RD, Leenstra S, Lafleur MV, Slotman BJ, Stalpers LJ and Sminia P: Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide. Br J Cancer 103: 29-35, 2010.
10. Persano L, Pistollato F, Rampazzo E, Della PA, Abbadi S, Frasson C, Volpin F, Indraccolo S, Scienza R and Basso G: BMP2 sensitizes glioblastoma stem-like cells to temozolomide by affecting HIF-1alpha stability and MGMT expression. Cell Death Dis 3: e412, 2012.
11. Xiao Z, Liu Q, Zhao B, Wu J and Lei T: Hypoxia induces hemorrhagic transformation in pituitary adenomas via the HIF-1α signaling pathway. Oncol Rep 26: 1457-1464, 2011.
12. Losa M, Mazza E, Terreni MR, McCormack A, Gill AJ, Motta M, Cangi MG, Talarico A, Mortini P and Reni M: Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases. Eur J Endocrinol 163: 843-851, 2010.
13. Wang X, Ma Z, Xiao Z, Liu H, Dou Z, Feng X and Shi H: Chk1 knockdown confers radiosensitization in prostate cancer stem cells. Oncol Rep 28: 2247-2254, 2012.
14. Yang J, Xiao Z, Li T, Gu X and Fan B: Erythropoietin promotes the growth of pituitary adenomas by enhancing angiogenesis. Int J Oncol 40: 1230-1237, 2012.
15. Naumann SC, Roos WP, Jost E, Belohlavek C, Lennerz V, Schmidt CW, Christmann M and Kaina B: Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53. Br J Cancer 100: 322-333, 2009.
16. Sadones J, Michotte A, Veld P, Chaskis C, Sciot R, Menten J, Joossens EJ, Strauven T, D'Hondt LA, Sartenaer D, et al: MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma. Eur J Cancer 45: 146-153, 2009.
17. van Nifterik KA, van den Berg J, Stalpers LJ, Lafleur MV, Leenstra S, Slotman BJ, Hulsebos TJ and Sminia P: Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines. Int J Radiat Oncol Biol Phys 69: 1246-1253, 2007.
18. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB and Herman JG: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343: 1350-1354, 2000.
19. Neff LM, Weil M, Cole A, Hedges TR, Shucart W, Lawrence D, Zhu JJ, Tischler AS and Lechan RM: Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists. Pituitary 10: 81-86, 2007.
20. Raverot G, Sturm N, de Fraipont F, Muller M, Salenave S, Caron P, Chabre O, Chanson P, Cortet-Rudelli C, Assaker R, et al: Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab 95: 4592-4599, 2010.
21. Sharma S, Salehi F, Scheithauer BW, Rotondo F, Syro LV and Kovacs K: Role of MGMT in tumor development, progression, diagnosis, treatment and prognosis. Anticancer Res 29: 3759-3768, 2009.
22. Baumann P and West SC: Role of the human RAD51 protein in homologous recombination and double-stranded-break repair. Trends Biochem Sci 23: 247-251, 1998.
23. Syro LV, Ortiz LD, Scheithauer BW, Lloyd R, Lau Q, Gonzalez R, Uribe H, Cusimano M, Kovacs K and Horvath E: Treatment of pituitary neoplasms with temozolomide: a review. Cancer 117: 454-462, 2011.
24. Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, Bertorelle R, Bartolini S, Calbucci F, Andreoli A, et al: MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26: 2192-2197, 2008.
25. Takeshita A, Inoshita N, Taguchi M, Okuda C, Fukuhara N, Oyama K, Ohashi K, Sano T, Takeuchi Y and Yamada S: High incidence of low O6-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing's disease. Eur J Endocrinol 161: 553-559, 2009.
26. Jackson SP and Bartek J: The DNA-damage response in human biology and disease. Nature 461: 1071-1078, 2009.
27. Levy A, Hall L, Yeudall WA and Lightman SL: p53 gene mutations in pituitary adenomas: rare events. Clin Endocrinol 41: 809-814, 1994.
28. Hagen T, D'Amico G, Quintero M, Palacios-Callender M, Hollis V, Lam F and Moncada S: Inhibition of mitochondrial respiration by the anticancer agent 2-methoxyestradiol. Biochem Biophys Res Commun 322: 923-929, 2004.
29. Pribluda VS, Gubish ER Jr, Lavallee TM, Treston A, Swartz GM and Green SJ: 2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. Cancer Metastasis Rev 19: 173-179, 2000.
30. Verger E, Gil M, Yaya R, Vinolas N, Villa S, Pujol T, Quinto L and Graus F: Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. Int J Radiat Oncol Biol Phys 61: 185-191, 2005.